CLINICAL STUDY: INTERVENTIONAL CARDIOLOGY
Local intracoronary administration of antisense oligonucleotide against c-myc for the prevention of in-stent restenosis
Results of the randomized investigation by the thoraxcenter of antisense dna using local delivery and ivus after coronary stenting (ITALICS) trial
Michael J. B. Kutryk, MD, PhD*,
David P. Foley, MD, PhD*,
Marcel van den Brand, MD, PhD*,
Jaap N. Hamburger, MD, PhD*,
Willem J. van der Giessen, MD, PhD*,
Pim J. deFeyter, MD, PhD, FACC*,
Nico Bruining, PhD*,
Manel Sabate, MD, PhD* and
Patrick W. Serruys, MD, PhD, FACC*,*
* Department of Interventional Cardiology, Thoraxcenter, University Hospital Dijkzigt, Rotterdam, The Netherlands
Manuscript received December 7, 2000;
revised manuscript received October 4, 2001,
accepted October 26, 2001.
* Reprint requests and correspondence: Dr. Patrick W. Serruys, Thoraxcenter, Bd 418, University Hospital Dijkzigt, Dr Molewaterplein 40, 3015 GD, Rotterdam, The Netherlands. serruys{at}card.azr.nl
OBJECTIVES: This study was designed to determine whether antisense oligodeoxynucleotides (ODN) directed against the nuclear proto-oncogene c-myc could inhibit restenosis when given by local delivery immediately after coronary stent implantation.
BACKGROUND: Failure of conventional pharmacologic therapies to reduce the incidence of coronary restenosis after percutaneous revascularization techniques has prompted interest in the use of agents that target intracellular central regulatory mechanisms.
METHODS: Eighty-five patients were randomly assigned to receive either 10 mg of phosphorothioate-modified 15-mer antisense ODN or saline vehicle by intracoronary local delivery after coronary stent implantation. The primary end point was percent neointimal volume obstruction measured by computerized analysis of electrocardiogram-gated intravascular ultrasound (IVUS) at six-month follow-up. Secondary end points included clinical outcome and quantitative coronary angiography analysis.
RESULTS: Analysis of follow-up IVUS data was performed on 77 patients. In-stent volume obstruction was similar between groups (44 ± 16% and 46 ± 14%, placebo vs. ODN; p = 0.57; 95% confidence interval: 1.13 to 0.85). Minimum luminal diameter increased from 0.84 ± 0.36 and 0.90 ± 0.45 (p = 0.55) to 2.70 ± 0.37 and 2.80 ± 0.37 (p = 0.28) after stent implantation, which decreased to 1.50 ± 0.61 and 1.50 ± 0.53 (p = 0.98) by six months, yielding similar loss indexes (placebo vs. ODN, respectively). There were no differences in angiographic restenosis rates (38.5 and 34.2%; p = 0.81; placebo vs. ODN) or clinical outcome.
CONCLUSIONS: Treatment with 10 mg of phosphorothioate-modified ODN directed against c-myc does not reduce neointimal volume obstruction or the angiographic restenosis rate in this patient population.
|
Abbreviations and Acronyms
| | AS-ODN | | antisense oligodeoxyribonucleotide | | CK | | creatine kinase | | IVUS | | intravascular ultrasound | | mRNA | | messenger RNA | | ODN | | oligodeoxyribonucleotide | | QCA | | quantitative coronary analysis |
|
This article has been cited by other articles:

|
 |

|
 |
 
T. H. Wang, D. L. Bhatt, and E. J. Topol
Aspirin and clopidogrel resistance: an emerging clinical entity
Eur. Heart J.,
March 2, 2006;
27(6):
647 - 654.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. A. Costa and D. I. Simon
Molecular Basis of Restenosis and Drug-Eluting Stents
Circulation,
May 3, 2005;
111(17):
2257 - 2273.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Hayashi, H. Banno, K. Kadomatsu, Y. Takei, K. Komori, and T. Muramatsu
Antisense oligodeoxyribonucleotide as to the growth factor midkine suppresses neointima formation induced by balloon injury
Am J Physiol Heart Circ Physiol,
May 1, 2005;
288(5):
H2203 - H2209.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Chandiwal, V. Balasubramanian, Z. K. Baldwin, M. S. Conte, and L. B. Schwartz
Gene Therapy for the Extension of Vein Graft Patency: A Review
Vascular and Endovascular Surgery,
January 1, 2005;
39(1):
1 - 14.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
J. W. Moses, M. B. Leon, J. J. Popma, P. J. Fitzgerald, D. R. Holmes, C. O'Shaughnessy, R. P. Caputo, D. J. Kereiakes, D. O. Williams, P. S. Teirstein, et al.
Sirolimus-Eluting Stents versus Standard Stents in Patients with Stenosis in a Native Coronary Artery
N. Engl. J. Med.,
October 2, 2003;
349(14):
1315 - 1323.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Hedman, J. Hartikainen, M. Syvanne, J. Stjernvall, A. Hedman, A. Kivela, E. Vanninen, H. Mussalo, E. Kauppila, S. Simula, et al.
Safety and Feasibility of Catheter-Based Local Intracoronary Vascular Endothelial Growth Factor Gene Transfer in the Prevention of Postangioplasty and In-Stent Restenosis and in the Treatment of Chronic Myocardial Ischemia: Phase II Results of the Kuopio Angiogenesis Trial (KAT)
Circulation,
June 3, 2003;
107(21):
2677 - 2683.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. E. Sousa, P. W. Serruys, and M. A. Costa
New Frontiers in Cardiology: Drug-Eluting Stents: Part II
Circulation,
May 13, 2003;
107(18):
2383 - 2389.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
I. D. Cox, C. A. Thompson, and S. N. Oesterle
Biointerventional cardiovascular therapy
Eur. Heart J.,
November 2, 2002;
23(22):
1753 - 1756.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. N. Kipshidze, H.-S. Kim, P. Iversen, H. A. Yazdi, B. Bhargava, G. New, R. Mehran, F. Tio, C. Haudenschild, G. Dangas, et al.
Intramural coronary delivery of advanced antisense oligonucleotides reduces neointimal formation in the porcine stent restenosis model
J. Am. Coll. Cardiol.,
May 15, 2002;
39(10):
1686 - 1691.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|